Navigation Links
Arbel Medical has Completed a $4.5 million Round of Capital Raising led by Giza Venture Capital Fund
Date:7/17/2008

YOKNEAM, Israel, July 17 /PRNewswire/ -- Arbel Medical, an Israeli start-up developing the next generation of medical equipment for removing tumors by freezing (cryotherapy), has completed raising $4.5 million of capital in its second round, led by the Giza Venture Capital fund.

The Docor International investment company, of the Van Leer group, has invested $1 million, joining the other Arbel investors who include Giza Venture Capital, Ofer High Tech, the Bridge Investment Fund from the USA, TRD and Fattal.

Dr Alon Dumanis, CEO of Docor, will be appointed as a member of the Board of Directors of Arbel Medical.

Arbel Medical works in the field of minimal-invasive treatments. The company is developing next generation medical devices for removing tumors by freezing (cryotherapy). Cryotherapy is currently considered as the most promising minimally invasive technique for removing tumors, a market that, according to MedMarket Diligence, is expected to grow at a rate of 30% a year in the coming decade. Arbel Medical brings promising news to women's health treatments, a market worth billions of dollars. Quick and effective treatment using Arbel's innovative device can even be carried out in clinics outside hospitals.

It should be noted that Arbel Medical was chosen as one of the three most promising start-ups in Israel in 2007 by the Export Institute, the Israel Life Sciences Institute (ILSI) and LSA.

Didier Toubia, Co-Founder of Arbel Medical, said that "the current round of capital raising provides the company important leverage to accelerate and expand its clinical trials overseas, establish itself in the American market, and launch its first product onto this market in 2009."

Elka Nir, a Partner in Giza and Chairperson of the Board of Directors of Arbel Medical, said: "Arbel is developing an innovative solution that meets a considerable need in the market and will provide a substitute for many of the surgical operations carried out in this field. We've been impressed by Arbel's achievements, including FDA approval, and are certain that Giza's global connections, experience and capabilities in the field of medical equipment will help the company fulfill its business vision.

We welcome Docor International joining the group of investors and the board of Directors, and are sure that they will make a great contribution to the Company."

Dr Alon Dumanis, CEO of Docor International, says: "After examining the company's capabilities and the market potential, it is our impression that Arbel's product is based on a ground-breaking technology that has already created considerable interest in the medical community. We are delighted to add Arbel Medical to Docor's portfolio, and intend to help the company meet its business goals with our experience and know-how in the field of life sciences."

About Arbel Medical

Arbel Medical, established in 2006, is active in the field of minimal-invasive treatments. The company is developing next generation medical devices for removing tumors by freezing (cryotherapy).

Among Arbel Medical's investors are Giza Venture Capital, which led the last capital raising round, the Ofer High Tech Group, the US-based Bridge Investment Fund, Docor International, TRD and Fattal.

About Docor International B.V

A leading investment group, Docor International B.V is part of the Van Leer Group Foundation. Docor invests in advanced technology-based companies with an Israeli presence, that make a significant contribution to the local economy. It focuses on companies in the life sciences, information technology and on industrial sectors with innovative technologies.

About Giza Venture Capital

Giza Venture Capital was established in 1992 and was one of the first Israeli investors specializing in early stage and seed investment. Giza manages around $500 million in four funds, and has invested in 87 companies with 32 exits to date.

Giza focuses in the fields of communications, semi-conductors, software, IT, internet, new media, and life sciences, and has offices in Tel Aviv and Singapore.

For additional information: http://www.arbel-medical.com or Didier Toubia, Co-Founder of Arbel Medical, toubia@arbel-medical.com. tel: +972-49090000


'/>"/>
SOURCE Arbel Medical
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
2. Saving Certified Continuing Medical Education (CME)
3. ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve
4. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
5. RADI Medical Systems Launches Next Generation PressureWire(R) Certus
6. BioElectronics ActiPatch(TM) Product Chosen as One of 9 Medical Breakthroughs That May Change Your Life
7. Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing
8. Oridion Wins 2008 Manufacturers Partnership Award From Independent Medical Distributors Association
9. Polymathic Analytical Labs Debuts at World's Largest Medical Design & Manufacturing Exhibition
10. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
11. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... 2016   EpiBiome , a precision microbiome engineering ... debt financing from Silicon Valley Bank (SVB). The financing ... advance its drug development efforts, as well as purchase ... "SVB has been an incredible strategic partner to us ... bank would provide," said Dr. Aeron Tynes Hammack ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
Breaking Biology Technology:
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):